AU9301998A - Composition and methods using galectin-1 - Google Patents

Composition and methods using galectin-1

Info

Publication number
AU9301998A
AU9301998A AU93019/98A AU9301998A AU9301998A AU 9301998 A AU9301998 A AU 9301998A AU 93019/98 A AU93019/98 A AU 93019/98A AU 9301998 A AU9301998 A AU 9301998A AU 9301998 A AU9301998 A AU 9301998A
Authority
AU
Australia
Prior art keywords
galectin
composition
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU93019/98A
Inventor
Moon-Jae Cho
Richard D. Cummings
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Oklahoma
Original Assignee
University of Oklahoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/924,289 external-priority patent/US6054315A/en
Priority claimed from US08/929,291 external-priority patent/US5948628A/en
Application filed by University of Oklahoma filed Critical University of Oklahoma
Publication of AU9301998A publication Critical patent/AU9301998A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis
AU93019/98A 1997-09-05 1998-09-03 Composition and methods using galectin-1 Abandoned AU9301998A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08929291 1997-09-05
US08924289 1997-09-05
US08/924,289 US6054315A (en) 1997-09-05 1997-09-05 Method for making activated neutrophils recognizable to macrophages
US08/929,291 US5948628A (en) 1997-09-05 1997-09-05 Methods of screening for compounds which mimic galectin-1
PCT/US1998/018371 WO1999012041A1 (en) 1997-09-05 1998-09-03 Composition and methods using galectin-1

Publications (1)

Publication Number Publication Date
AU9301998A true AU9301998A (en) 1999-03-22

Family

ID=27129885

Family Applications (1)

Application Number Title Priority Date Filing Date
AU93019/98A Abandoned AU9301998A (en) 1997-09-05 1998-09-03 Composition and methods using galectin-1

Country Status (2)

Country Link
AU (1) AU9301998A (en)
WO (1) WO1999012041A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558916B2 (en) 1996-08-02 2003-05-06 Axiom Biotechnologies, Inc. Cell flow apparatus and method for real-time measurements of patient cellular responses
US5804436A (en) 1996-08-02 1998-09-08 Axiom Biotechnologies, Inc. Apparatus and method for real-time measurement of cellular response
US6280967B1 (en) * 1996-08-02 2001-08-28 Axiom Biotechnologies, Inc. Cell flow apparatus and method for real-time of cellular responses
US7396529B2 (en) 2001-01-12 2008-07-08 Mount Sinai Hospital Compositions and methods for regulating receptor clustering
US20060009378A1 (en) 2002-11-14 2006-01-12 Itshak Golan Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases
CA2505931A1 (en) * 2002-11-14 2004-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases
US20070190528A1 (en) * 2003-08-18 2007-08-16 Toshihiro Tanaka Method of judging imflammatory disease by using single nucleotide polymorphism in galectin -2 gene
US7189697B2 (en) * 2004-04-13 2007-03-13 Trustees Of Tufts College Compositions and uses of a galectin for treatment of dry eye syndrome
WO2008127355A2 (en) 2006-10-06 2008-10-23 Celtaxsys, Inc. Chemorepulsion of cells
US9939428B2 (en) 2007-07-17 2018-04-10 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, and monitoring of immune disorders using galectin-1
US9206427B2 (en) 2007-07-17 2015-12-08 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the modulation of immune responses using galectin-1
GB201110777D0 (en) 2011-06-24 2011-08-10 Aqua Bio Technology Asa Methods and uses
US11603394B2 (en) 2016-10-04 2023-03-14 University Of Florida Research Foundation, Incorporated Targeted effector proteins and uses thereof
US11407797B2 (en) 2017-10-11 2022-08-09 University Of Florida Research Foundation, Incorporated Modified gal-1 proteins and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2983224B2 (en) * 1988-04-14 1999-11-29 インサイト ファーマシューティカルズ，インコーポレイテッド Mammalian 14-β-gal lectins
GB9023907D0 (en) * 1990-11-02 1990-12-12 Mallucci Livio Cell growth inhibitors
AU5608594A (en) * 1992-11-16 1994-06-08 Incyte Pharmaceuticals, Inc. Method of causing selective immunosuppression using hl-60-related lectins

Also Published As

Publication number Publication date
WO1999012041A1 (en) 1999-03-11

Similar Documents

Publication Publication Date Title
AU7275098A (en) Enhanced adenovirus-assisted transfection composition and method
AU3641597A (en) Methods and compositions comprising r-ibuprofen
AU9790198A (en) Compounds and methods
AU4208799A (en) Interleukins-21 and 22
AU5752398A (en) Novel ketobenzamides and their use
AU1919295A (en) Aminophospholipid compositions and uses thereof
AU4266596A (en) Composition and use
AUPO976797A0 (en) Method and composition (III)
AU2349399A (en) R-lansoprazole compositions and methods
AU9781998A (en) Huchordin and uses thereof
AU2972597A (en) Compositions and uses thereof
AU5828098A (en) Texture and stabilizer composition
AU4215399A (en) Dermatological compositions and methods
AUPO976597A0 (en) Method and composition (I)
AU5335798A (en) Stomatic composition
AU9301998A (en) Composition and methods using galectin-1
AU8747498A (en) Food-preservative composition
AU7685798A (en) Compositions and methods for preventing adhesion
AU4876397A (en) Insecticidal compositions and methods
AU8121998A (en) Composition
AU3200197A (en) New composition and methods
AU7364598A (en) Coating composition and method
AU1098499A (en) Emulsifier-lipid composition
AUPO982097A0 (en) Methods and compositions for use therein
AU2980799A (en) Lectomedin materials and methods

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase